Doximity, Inc. (NASDAQ:DOCS) Receives Average Rating of “Moderate Buy” from Analysts

Doximity, Inc. (NASDAQ:DOCS) has received a consensus rating of “Moderate Buy” from the twenty-one brokerages that are presently covering the company, MarketBeat.com reports. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $64.22.

DOCS has been the topic of several analyst reports. Truist Financial lifted their target price on Doximity from $35.00 to $49.00 and gave the company a “hold” rating in a research note on Thursday, November 14th. Mizuho raised their price target on Doximity from $55.00 to $65.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Raymond James reaffirmed an “outperform” rating and set a $83.00 target price (up previously from $65.00) on shares of Doximity in a report on Friday, February 7th. Morgan Stanley raised Doximity from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $33.00 to $53.00 in a report on Thursday, November 14th. Finally, Needham & Company LLC boosted their price target on Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 7th.

Insider Buying and Selling

In related news, Director Timothy S. Cabral sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 37.40% of the stock is owned by company insiders.

Institutional Trading of Doximity

Several large investors have recently made changes to their positions in the company. QSV Equity Investors LLC grew its holdings in Doximity by 0.3% in the 4th quarter. QSV Equity Investors LLC now owns 60,763 shares of the company’s stock valued at $3,244,000 after buying an additional 186 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in Doximity by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 29,700 shares of the company’s stock valued at $1,586,000 after buying an additional 200 shares in the last quarter. UMB Bank n.a. grew its holdings in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company’s stock valued at $31,000 after buying an additional 235 shares in the last quarter. Fielder Capital Group LLC grew its holdings in Doximity by 4.5% in the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock valued at $293,000 after buying an additional 235 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in Doximity by 49.4% in the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock valued at $40,000 after buying an additional 250 shares in the last quarter. 87.19% of the stock is currently owned by hedge funds and other institutional investors.

Doximity Price Performance

DOCS opened at $61.64 on Wednesday. The business’s 50-day moving average is $63.11 and its two-hundred day moving average is $52.16. Doximity has a 1 year low of $22.96 and a 1 year high of $85.21. The firm has a market capitalization of $11.51 billion, a PE ratio of 61.64, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.